TMCnet News
NetNoggin® announces the release of NetNog: #genesis® NASH (including NAFL)FREDERICK, Md., May 21, 2019 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Nonalcoholic Steatohepatitis (NASH) (including Nonalcoholic Fatty Liver [NAFL]). Learn more: https://netnoggin.net/disease-focused-research. NetNog: #genesis® NASH (including NAFL) offers pharmaceutical companies an unprecedented advantage by starting their product development with a disease-focused guide, which:
"NASH and NAFL are underdeveloped markets with no approved treatments, sounderstanding the patient's needs, from a netnographic perspective, provides our clients with a great opportunity to change the trajectory of this disease and the patient's quality of life," said Diana Conger, Chief Executive Officer of NetNoggin®. "Recently, NetNog: #genesis® helped a client align their late phase clinical trials with their commercialization strategy. Our insights led to revised clinical trial protocol, positioning, and targeting." NetNog: #genesis® is foundational research grounded in netnography (unframed, unbiased, online immersion into patients', caregivers', and HCPs' real world conversations and supported with secondary research to provide context to the disease state. NASH (including NAFL) is the third disease state published in the NetNog: #genesis® portfolio. Also included in the portfolio are Cystic Fibrosis and Alzheimer's Disease (including MCI). Visit https://netnoggin.net/disease-focused-research to learn more about NetNog: #genesis® NASH (including NAFL) and upcoming reports. About NetNoggin® NetNoggin® Media Relations If you would like more information about this topic, please contact Megan Newcomer. View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-announces-the-release-of-netnog-genesis-nash-including-nafl-300853644.html SOURCE NetNoggin, LLC |